Phase I trial of intravenous emulsion fenretinide in adults with hematological malignancies.
Patients with recurrent or refractory leukemia and lymphomas who meet other eligibility criteria are eligible for this study. The trial is being carried out in collaboration with the California Cancer Consortium and the National Cancer Institute.
Study Chair: Ann Morbacher, MD, University of Southern California.
SPOC Study Chair: Everardo Cobos, MD, TTUHSC.
Trial currently open at: TTUHSC
Phase I trial of intravenous emulsion fenretinide in adults with malignant solid tumors.
Patients with recurrent or refractory malignant solid tumors who meet other eligibility criteria are eligible for this study. The trial is being carried out in collaboration with the California Cancer Consortium and the National Cancer Institute.
Study Chairs: Jacek Pinski, MD PhD and Anthony El-Khoueiry, MD University of Southern California.
SPOC Study Chair: Everardo Cobos, MD, TTUHSC.
Trial currently open at: TTUHSC
Banking of Tissue and Establishing Continuous Cell Lines and Xenografts From Neoplasia
Study Chair: Simon Williams, PhD
Trial currently open at: TTUHSC and Covenant
A Phase I Study of Intravenous (Emulsion) Fenretinide (4-HPR, NSC 374551) in Children with Recurrent or Resistant Acute Lymphoblastic Leukemia (ALL), Acute Myelogeneous Leukemia (AML), and Non-Hodgkin's Lymphoma (NHL) IND #70,058
Study Chair: Anna R. K. Franklin, MD
1515 Holcombe Boulevard, Unit 0087
Houston, TX 77030-4009
Phone: 713-792-3497, 713-792-6620
Pager: 713-404-3804
Fax: 713-792-0608
E-mail: afranklin@mdanderson.org
Trial currently open at: pending
© South Plains Oncology Consortium (2008-2010)